Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.
1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable among patients in either group. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatocellular carcinoma comprises a predominant portion of primary liver malignancies. Immunotherapy combined with anti-angiogenic treatment has shown promise in various advanced solid tumors,
Whether or not late stage patients have access to the latest therapies or only cytotoxic chemotherapy; the treatment options are still only palliative and symptomatic. Symptomatic care refers to therapies intended to ease the symptoms and improve the patient’s quality of life (QoL) without addressing the basic cause of the disease.